Abstract
The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.
Original language | English (US) |
---|---|
Pages (from-to) | 1265-1266 |
Number of pages | 2 |
Journal | Blood |
Volume | 131 |
Issue number | 12 |
DOIs |
|
State | Published - Mar 22 2018 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology
Cite this
Consensus on MRD in AML? / Paietta, Elisabeth M.
In: Blood, Vol. 131, No. 12, 22.03.2018, p. 1265-1266.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Consensus on MRD in AML?
AU - Paietta, Elisabeth M.
PY - 2018/3/22
Y1 - 2018/3/22
N2 - The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.
AB - The European LeukemiaNet (ELN) Working Party publishes its consensus document on minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) in this issue of Blood; Schuurhuis et al’s article reports the status of existing methodologies for MRD assessments, provides guidelines for standardized approaches, and recommends future directions.
UR - http://www.scopus.com/inward/record.url?scp=85047650083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047650083&partnerID=8YFLogxK
U2 - 10.1182/blood-2018-01-828145
DO - 10.1182/blood-2018-01-828145
M3 - Comment/debate
C2 - 29567752
AN - SCOPUS:85047650083
VL - 131
SP - 1265
EP - 1266
JO - Blood
JF - Blood
SN - 0006-4971
IS - 12
ER -